Reverse Metabolomics for the Discovery of Disease Associated Microbial Molecules
Project Number5R01DK136117-02
Contact PI/Project LeaderDORRESTEIN, PIETER C
Awardee OrganizationUNIVERSITY OF CALIFORNIA, SAN DIEGO
Description
Abstract Text
Project Summary/Abstract
The Microbiota-Diet-Host interactions are critical to the balance of health and disease. Understanding
this axis will be important to the development of nutritional precision medicine. Although there are some
important discoveries where microbes make molecules that dramatically affect health, most of the molecules
produced by microbiota still remain structurally uncharacterized. In addition, even when a molecule is known
and the activity is known, this knowledge tends to be buried in papers and there is not a systematic
organization of this knowledge that can be readily leveraged by data scientists. This prevents a deep
mechanistic understanding of the microbiome. The goal of PAR-21-253 to which this application is applying to
and the accompanying RFA (RFA-DK-21-014) is to build a microbial metabolite knowledgebase that can be
used by the larger scientific community. In order to build the knowledgebase, the R01’s funded under PAR-21-
253 are discovery grants that will provide the knowledge of new microbial metabolites and their bioactivities.
This proposal will 1) obtain MS/MS signatures for up to 5,000,000 molecules synthesized, using
combinatorial/diversity driven synthesis, using diet and host precursors that are accessible to human
microbiota. The synthesis is biased towards common bio-transformations. This will be the largest
metabolomics reference data set ever assembled, even when all public and non-public libraries are combined;
2) we will use our big data mining strategies, especially our mass spectrometry search tools, to not only
discover what molecules are made by microbes, but also understand phenotype, disease, organ/tissue/biofluid,
food associations; 3) the newly discovered microbial molecules that are up or down regulated in inflammatory
bowel disease (and other gut metabolic disorders) will be further screened in cell-based assays and colitis
animal studies to understand the biological effects of the newly discovered microbial metabolites; 4) we will
transfer all the knowledge obtained by this R01 to the knowledgebase that will be created by the
accompanying RFA.
The PIs and Co-Is are well suited to help build the proposed knowledge base, due to their expertise in
microbial metabolomics (Dorrestein), synthesis (Dorrestein, Siegel), microbiome (Dorrestein, Knight,
Raffatellu), data science (Dorrestein, Knight) and having a track record of doing very large projects and share
newly discovered knowledge publicly for the benefit of the community – generally made available years before
any publication (Dorrestein, Knight).
Public Health Relevance Statement
Project Narrative
In the human body, for 100 human cells that are present, there are 130 microbial cells. Those
microbes often define the balance of human health and disease, yet the molecules by which
they promote this balance are unknown. We have designed a reverse metabolomics and big
data mining strategy to discover microbial metabolites with emphasis on microbial metabolites
associated with inflammatory bowel disease and other gut associated metabolic
disorders.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
847
DUNS Number
804355790
UEI
UYTTZT6G9DT1
Project Start Date
15-May-2023
Project End Date
29-February-2028
Budget Start Date
01-March-2024
Budget End Date
28-February-2025
Project Funding Information for 2024
Total Funding
$721,727
Direct Costs
$464,312
Indirect Costs
$257,415
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Diabetes and Digestive and Kidney Diseases
$721,727
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01DK136117-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01DK136117-02
Patents
No Patents information available for 5R01DK136117-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01DK136117-02
Clinical Studies
No Clinical Studies information available for 5R01DK136117-02
News and More
Related News Releases
No news release information available for 5R01DK136117-02
History
No Historical information available for 5R01DK136117-02
Similar Projects
No Similar Projects information available for 5R01DK136117-02